Please assess the completion status of the following clinical trial:

Trial Title: The Role of Montelukast in Rhinitis and Sleep

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Inclusion criteria will include:~1. Age 16 to 65.~2. History of allergic rhinitis.~3. The ability to be placed on placebo without significant compromise in the quality of life.~4. General good health.~5. Ability to comply with the protocol and sign an informed consent.~6. Have daytime sleepiness by history.~7. Have poor sleep by history.~8. Have fatigue by history.~9. Have a skin test or RAST test to a perennial allergen (indoor mold, dog, cat, mite) with correlating symptoms.~Exclusion Criteria:~1. Age fewer than 16 or over 65 years.~2. A history of sleep apnea.~3. Atopic diseases other than allergic rhinitis, such as atopic dermatitis or asthma.~4. Non-allergic rhinitis.~5. Obesity.~6. Inability to tolerate montelukast.~7. Significant other diseases as determined by the investigator.~8. Use of a research medication within 30 days.~9. Use of a nasal steroid or topical antihistamine or decongestant within 30 days.~10. Use of beta-blockers, antidepressants, oral decongestants, oral steroids, or H2-blockers.~11. Excessive use of alcohol or drug abuse.~12. Inability to stop medication use during run-in period.~13. Use of an oral antihistamine within 1 week of enrollment.~14. Failed to have benefit when montelukast was used for rhinitis or asthma in the past

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- montelukast (Type: ACTIVE_COMPARATOR): montelukast 10 mg daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).